Form 4: Apellis Pharmaceuticals Chief Development Officer Sells Shares to Cover Tax Obligations

Apellis Pharmaceuticals' Chief Development Officer, Jeffrey Eisele, sold 264 shares of common stock to cover tax withholding obligations related to restricted stock units.

Summary

• Jeffrey Eisele, Chief Development Officer of Apellis Pharmaceuticals, sold 264 shares of common stock on January 13, 2025.
• The sale was executed at a price of $28.7021 per share.
• This transaction was to cover tax withholding obligations related to restricted stock units that were released on January 10, 2025.
• Following the transaction, Mr. Eisele directly owns 56,881 shares of Apellis Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: This is a routine transaction related to tax obligations and does not indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across the pharmaceutical industry.
• These transactions are typically disclosed through SEC Form 4 filings, which are standard for all publicly traded companies in the US.
• The number of shares sold is relatively small compared to the total holdings of the executive, which is typical in these types of transactions.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a small sale by an executive to cover tax obligations.

Key Dates

Keywords

Apellis Pharmaceuticals, Jeffrey Eisele, stock sale, insider trading, Form 4, tax withholding, restricted stock units